How have EMMA shares performed in 2024?

Emmaus Life Sciences' stock was trading at $0.1001 at the beginning of 2024. Since then, EMMA shares have decreased by 8.0% and is now trading at $0.0921. View the best growth stocks for 2024 here .

Are investors shorting Emmaus Life Sciences?

Emmaus Life Sciences saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 800 shares, a decline of 89.5% from the March 15th total of 7,600 shares. Based on an average daily trading volume, of 12,400 shares, the days-to-cover ratio is presently 0.1 days. View Emmaus Life Sciences' Short Interest .

How do I buy shares of Emmaus Life Sciences?

Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:EMMA

Emmaus Life Sciences (EMMA) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free EMMA Stock Alerts

$0.09

-0.02 (-17.86%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.09
▼
$0.10
50-Day Range: $0.09
▼
$0.13
52-Week Range: $0.05
▼
$0.34

Volume: 66,100 shs
Average Volume: 20,455 shs
Market Capitalization: $5.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

Get Emmaus Life Sciences alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Emmaus Life Sciences Stock (OTCMKTS:EMMA)

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

EMMA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EMMA Stock News Headlines

April 17, 2024 | msn.com

District 11 wrestling: Kinney, Fanelli, Smith earn Scholar-Athlete awards

April 15, 2024 | finance.yahoo.com

Emmaus Life Sciences Reports Delayed Filing of Annual Report

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 10, 2024 | chicago.suntimes.com

The Museum of Science and Industry closed for mysterious reasons last week. Here’s why

April 10, 2024 | investing.com

Emmaus Life Sciences Inc (EMMA)

April 4, 2024 | msn.com

Peabody Museum Review: Smearing Science

March 27, 2024 | wsj.com

Emmaus Life Sciences Inc.

February 24, 2024 | msn.com

Homeless charity seeks volunteers to help with eBay operations

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 23, 2024 | msn.com

Discovery World named one of the best science museums in USA Today's 10Best Readers' Choice Awards

February 22, 2024 | msn.com

Texas Tech University Health Sciences Center announces Simulation Program reaccreditation

February 18, 2024 | abcnews.go.com

Saving democracy is central to Biden's campaign. Will it resonate with voters?

February 2, 2024 | finance.yahoo.com

Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico

February 1, 2024 | msn.com

Science Museum of Western Virginia announces grand opening of ‘The Eye’

January 18, 2024 | msn.com

Emmaus wrestlers roll their way over “flat” Freedom

January 17, 2024 | news.yahoo.com

Transgender row at Science Museum over claims reworked exhibit is 'even more insidious'

January 12, 2024 | msn.com

Biden says Austin still has his confidence, but not revealing hospitalization was lapse in judgment

January 8, 2024 | msn.com

Denver Museum of Nature & Science gets makeover with East Wing renovation project

January 4, 2024 | sfgate.com

A local guide to science museums near San Francisco

January 4, 2024 | msn.com

Science Museum of Minnesota receives largest gift in organization's history

November 17, 2023 | msn.com

The Museum of Illusions in Philadelphia meets science with immersive fun

November 14, 2023 | cbsnews.com

New exhibit at the Academy of Natural Sciences takes you back millions of years into history

November 14, 2023 | finanznachrichten.de

Emmaus Life Sciences, Inc.: Emmaus Life Sciences Reports Q3 2023 Financial Results

November 14, 2023 | msn.com

Emmaus Life Sciences GAAP EPS of -$0.01, revenue of $5M

November 14, 2023 | finance.yahoo.com

Emmaus Life Sciences Reports Q3 2023 Financial Results

November 10, 2023 | msn.com

Seattle nonprofit wants to help all students love math, using school programs and in-person exhibits

November 10, 2023 | msn.com

Best Museums for Kids in Philly: Children’s Museums and Family-Friendly Museums

See More Headlines

Receive EMMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:EMMA
CUSIP: N/A
CIK: 822370
Web: www.emmausmedical.com
Phone: (310) 214-0065
Fax: 866-294-2611
Employees: 54
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,620,000.00
Net Margins: -16.66%
Pretax Margin: -16.42%
Return on Equity: N/A
Return on Assets: -9.73%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.15
Quick Ratio: 0.12

Sales & Book Value

Annual Sales: $18.39 million
Price / Sales: 0.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.69) per share
Price / Book: -0.16

Miscellaneous

Outstanding Shares: 61,850,000
Free Float: 40,200,000
Market Cap: $7.04 million
Optionable: Not Optionable
Beta: 1.61

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Willis C. Lee M.S. (Age 64)
Co-President, COO & Chairman of the Board
Comp: $240k
Mr. Yasushi Nagasaki CPA (Age 57)
CPA, Chief Financial Officer
Comp: $250k
Mr. George Sekulich (Age 58)
Co-President, Chief Commercial Officer & Director
Mr. Dale E. Short J.D.
Legal Consultant & Corporate Secretary
Dr. Charles W. Stark Pharm.D (Age 69)
Pharm.D., Senior Vice President of Medical Affairs, Clinical, Regulatory
Mr. Kurt H. Kruger M.B.A. (Age 69)
M.S., Consultant
Comp: $300.02k

Key Competitors

View All Competitors

EMMA Stock Analysis - Frequently Asked Questions

How have EMMA shares performed in 2024?: Emmaus Life Sciences' stock was trading at $0.1001 at the beginning of 2024. Since then, EMMA shares have decreased by 8.0% and is now trading at $0.0921.
View the best growth stocks for 2024 here.
Are investors shorting Emmaus Life Sciences?: Emmaus Life Sciences saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 800 shares, a decline of 89.5% from the March 15th total of 7,600 shares. Based on an average daily trading volume, of 12,400 shares, the days-to-cover ratio is presently 0.1 days.
View Emmaus Life Sciences' Short Interest.
How do I buy shares of Emmaus Life Sciences?: Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:EMMA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Emmaus Life Sciences (EMMA) Stock Price, News & Analysis

About Emmaus Life Sciences Stock (OTCMKTS:EMMA)

EMMA Stock Price History

EMMA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

EMMA Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info